Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Jensen

Showing results (11-20 of 134) with videos related to

Pageof 14
Sort By:
Biotechnology and Bioengineering|March 27, 2015
Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selectionNataly Kacherovsky, Gary W Liu, Michael C Jensen, et al.
Accounts of Chemical Research|August 14, 2020
Biomaterials in Chimeric Antigen Receptor T-Cell Process DevelopmentIan I Cardle, Emmeline L Cheng, Michael C Jensen, et al.
The Journal of Biological Chemistry|April 15, 2021
Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targetingIan I Cardle, Michael C Jensen, Suzie H Pun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2010
Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapyDarya Alizadeh, Leying Zhang, Christine E Brown, et al.
Cancer Immunology Research|July 3, 2016
ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsEugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, et al.
Cancer Immunology Research|April 10, 2016
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsEugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiformeJelena Lazovic, Michael C Jensen, Evette Ferkassian, et al.
ACS Nano|January 27, 2025
<i>In Situ</i> Bioconjugation of Synthetic Peptides onto Universal Chimeric Antigen Receptor T Cells for Targeted Cancer ImmunotherapiesIan I Cardle, Dylan R Scherer, Michael C Jensen, et al.
The Journal of Clinical Investigation|December 7, 2007
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesCarolina Berger, Michael C Jensen, Peter M Lansdorp, et al.
Molecular Immunology|April 17, 2012
Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptorMegan E Prosser, Christine E Brown, Andrew F Shami, et al.
Pageof 14

Showing results (11-20 of 134) with videos related to

Sort By:
Pageof 14
Biotechnology and Bioengineering|March 27, 2015
Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selectionNataly Kacherovsky, Gary W Liu, Michael C Jensen, et al.
Accounts of Chemical Research|August 14, 2020
Biomaterials in Chimeric Antigen Receptor T-Cell Process DevelopmentIan I Cardle, Emmeline L Cheng, Michael C Jensen, et al.
The Journal of Biological Chemistry|April 15, 2021
Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targetingIan I Cardle, Michael C Jensen, Suzie H Pun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2010
Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapyDarya Alizadeh, Leying Zhang, Christine E Brown, et al.
Cancer Immunology Research|July 3, 2016
ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsEugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, et al.
Cancer Immunology Research|April 10, 2016
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsEugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiformeJelena Lazovic, Michael C Jensen, Evette Ferkassian, et al.
ACS Nano|January 27, 2025
<i>In Situ</i> Bioconjugation of Synthetic Peptides onto Universal Chimeric Antigen Receptor T Cells for Targeted Cancer ImmunotherapiesIan I Cardle, Dylan R Scherer, Michael C Jensen, et al.
The Journal of Clinical Investigation|December 7, 2007
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesCarolina Berger, Michael C Jensen, Peter M Lansdorp, et al.
Molecular Immunology|April 17, 2012
Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptorMegan E Prosser, Christine E Brown, Andrew F Shami, et al.
Pageof 14